細胞材料開発室　-CELL BANK-

(最終更新日:2021年3月24日)

1）新型コロナウイルス感染症に対する理研BRCの取り組み

理研バイオリソース研究センター(理研BRC)は、遺伝子/細胞/マウス個体の三つの生命階層のリソースを1機関で取り揃えた、世界的にもユニークなリソース機関です。この特徴を活かして、新型コロナウイルス感染症の統合的な研究の促進のため、感染症の4つのステージ（①ウイルス感染・増殖、②発症・生体防御、③重症化、④治療・予防）の研究開発の鍵となるバイオリソースを収集・整備し、情報発信していきます。

COVID-19 関連マウスリソース(実験動物開発室）

SARS-CoV-2 relevant human genes(遺伝子材料開発室）

---

2）COVID-19 関連寄託細胞株

Reference	BRC Resource	特性
Potent mouse monoclonal antibodies that block SARS-CoV-2 infection	RCB5391 R52_Spike	抗SARS-CoV-2 Spike抗体(Clone R52)を産生するハイブリドーマ。
	RCB5392 S1D7_Spike	抗SARS-CoV-2 Spike抗体(Clone S1D7)を産生するハイブリドーマ。
	RCB5393 S3D8_Spike	抗SARS-CoV-2 Spike抗体(Clone S3D8)を産生するハイブリドーマ。

---

3）BRCから提供した細胞を利用した COVID-19 関連文献

	BRC Resource	Reference
1	RCB2202 293T	Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry
2	RCB0485 LA-N-5	Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19
3	RCB0988 CACO-2 CSII-CMV-MCS-IRES2-Bsd	SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells
4	RCB0995 MDCK	Survival of SARS-CoV-2 and influenza virus on the human skin: Importance of hand hygiene in COVID-19
5	RCB2202 293T	An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies
6	RCB0535 RAW 264	Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2
7	RCB1945 HSC-2	Expression of SARS‐CoV‐2 entry factors in human oral tissue
8	RCB0209 SP2/0-Ag14	Potent mouse monoclonal antibodies that block SARS-CoV-2 infection
9	RCB2350 StromaNKtert	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

---

4）COVID-19 研究のための細胞株

	BRC Cell Line	Cell Line	Reference
1	Vero E6, RCB0001 Vero RCB0988 CACO-2 Calu-3 RCB2202 293T RCB1366 HuH-7	Vero E6 Caco-2 Calu-3 HEK293T Huh7	In Vitro and Animal Models for SARS-CoV-2 research
2	Vero E6 RCB0001 Vero RCB1366 HuH-7 RCB2202 293T RCB0098 A549, RCB3677 A549 EFKB3	Vero E6 Vero HUH 7.0 293T A549 EFKB3	Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States
3	RCB0001 Vero RCB0007 HeLa, RCB3680 HeLa RCB2202 293T RCB1366 HuH-7	Vero HeLa HEK293T/F Huh7	A Thermostable mRNA Vaccine against COVID-19
4	RCB1637 293 RCB2202 293T RCB0098 A549, RCB3677 A549 RCB0218 MRC-5, known PDL Vero E6, RCB0001 Vero Vero 81 RCB0007 HeLa, RCB3680 HeLa RCB1366 HuH-7	293 293T A549 MRC5 Vero E6 Vero 81 HeLa Huh7	Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
5	RCB1648 Hep G2 RCB1366 HuH-7 RCB2202 293T RCB0001 Vero CHO RCB0995 MDCK	HepG2 Huh-7 293T Vero CHO MDCK	Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
6	Vero E6, RCB0001 Vero RCB1366 HuH-7	Vero E6 Huh-7	Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
7	Vero E6, RCB0001 Vero RCB1366 HuH-7	Vero E6 Huh-7	Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway
8	Vero E6, RCB0001 Vero RCB1366 HuH-7	Vero E6 Huh-7	Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
9	Vero E6, RCB0001 Vero RCB1366 HuH-7	Vero E6 Huh-7	A pneumonia outbreak associated with a new coronavirus of probable bat origin
10	RCB1637 293 RCB1366 HuH-7 RCB1423 BHK-21 Vero E6, RCB0001 Vero	HEK293 Huh-7 BHK21 Vero-E6	Middle East Respiratory Syndrome Coronavirus ORF8b Accessory Protein Suppresses Type I IFN Expression by Impeding HSP70-Dependent Activation of IRF3 Kinase IKKε
11	RCB0007 HeLa, RCB3680 HeLa RCB2202 293T RCB1423 BHK-21 RCB0988 CACO-2	HeLa 293T BHK-21 Caco-2	COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome
12	RCB0988 CACO-2	Caco-2	Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
13	RCB0988 CACO-2	Caco-2	A metabolic handbook for the COVID-19 pandemic
14	RCB2202 293T RCB0098 A549, RCB3677 A549 BHK RCB0988 CACO-2 RCB1366 HuH-7 PK-15	293T A549 BHK Caco-2 Huh-7.5 PK-15	Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
15	RCB2202 293T RCB0098 A549, RCB3677 A549	HEK293T A549	Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
16	RCB2202 293T RCB0007 HeLa, RCB3680 HeLa Calu-3 RCB0218 MRC-5, known PDL	HEK293T HeLa Calu-3 MRC-5	Cell entry mechanisms of SARS-CoV-2
17	RCB2202 293T HEK293F RCB0007 HeLa, RCB3680 HeLa RCB0218 MRC-5, known PDL	HEK293T HEK293F HeLa MRC5	Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
18	RCB1366 HuH-7 Huh-7.5	Huh-7 Huh-7.5	Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication
19	RCB0994 MA104 RCB1637 293	MA104 HEK293	TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
20	RCB0218 MRC-5, known PDL	MRC-5	Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells
21	Fcwf-4 A72 RCB0995 MDCK DH82	Fcwf-4 A72 MDCK DH82	Establishment of a Virulent Full-Length cDNA Clone for Type I Feline Coronavirus Strain C3663
22	GES-1 RCB1189 THP-1,RCB3686 THP-1	GES-1 THP-1	Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels